GSTM1 and chronic hepatitis B virus infection: Functional cure in terms of HBsAg loss and the development of anti-HB antibodies (seroconversion) should be the ultimate goal in the treatment of patients with chronic hepatitis B with regard to drug withdrawal safety and improvements in prognosis.